DES PLAINES, Ill., March 7, 2008 - Abbott today announced that its molecular diagnostics business has entered into an agreement with Genentech, Inc., F. Hoffmann-La Roche Ltd. and OSI Pharmaceuticals, Inc. to develop a gene test to potentially assess the clinical benefit of Tarceva (erlotinib), an oral tablet indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.» More

Des Plaines, Illinois, January 17, 2008 - Working in collaboration with leading international researchers in the area of sexually transmitted disease, Abbott has developed a newly formulated molecular test capable of detecting a new variant strain of Chlamydia trachomatis found in one in five chlamydia cases in Sweden.» More

ABBOTT PARK, Ill, Oct. 22, 2007 - Abbott has received a 2007 Chicago Innovation Award for its m2000 molecular diagnostic instrument and the Abbott RealTime HIV-1 viral load test, the most sensitive test of its kind capable of detecting and precisely measuring all known strains of the human immunodeficiency virus (HIV).» More

DELKENHEIM, Germany, June 21,2007 - Abbott and Celera, an Applera Corporation business, announced today that Abbott has received CE marking for a real-time PCR (polymerase chain reaction) test for monitoring hepatitis B (HBV) viral load in patients, allowing the test to be marketed in the European Union. Abbott is marketing the test under its strategic alliance with Celera.» More

MISSISSAUGA, Ontario, Jan. 8, 2007 - Abbott and Celera (NYSE:CRA), an Applera Corporation business, announced today that Health Canada has approved the Abbott m2000 automated instrument system and the Abbott RealTime HIV-1 and hepatitis C virus (HCV) viral load tests for marketing in Canada.» More

DES PLAINES, Ill., July 21, 2006 - Abbott Molecular will preview its new automated molecular diagnostics system, the m2000, at the annual meeting of the American Association for Clinical Chemistry (AACC) in Chicago (July 23-27). The m2000 is based on real-time polymerase chain reaction (PCR) technology for detecting and monitoring infectious diseases and is designed to provide clinical laboratories a unique system that fully automates all of the complex and heavily manual steps often associated with molecular diagnostics.» More

DES PLAINES, ILL., July 20, 2006 - A study published in the July 2006 edition of Journal of Urology has shown that UroVysion, a DNA-based urine test that detects important genetic changes in bladder cells, has almost twice the sensitivity of conventional urine cytology tests.» More

Abbott Park, Illinois, May 17, 2006 - A review of multiple studies in the journal Urology indicates that UroVysion?, a DNA-based urine test that detects key genetic changes in bladder cells, showed favorable clinical attributes not found in other available biomarkers in the detection of bladder cancer.» More

DELKENHEIM, Germany, Jan. 23, 2006 - Abbott today announced that a highly sensitive new test for the simultaneous detection of the sexually transmitted pathogens Chlamydia trachomatis (CT) and Neissera gonorrhoeae (NG) has received CE Mark certification, allowing it to be marketed in the European Union. The test is designed for use on the Abbott m2000?, an automated instrument using magnetic particle and real-time PCR (polymerase chain reaction) technology.» More

ABBOTT PARK, Ill., Oct. 11, 2005 - Abbott's PathVysion^® HER-2 DNA Probe Kit has been named a recipient of the 2005 Chicago Innovation Award. PathVysion was chosen among 130 submissions for the award, which recognizes innovative products that help improve consumer's lives.» More

DES PLAINES, Ill., Sept. 29, 2005 - Abbott today announced the dedication of a new facility in Des Plaines, Ill., devoted to the discovery, development and manufacturing of molecular diagnostic products for cancer, HIV and other medical conditions.» More

Donna Henagin was a strong, physically active young woman when she was diagnosed with breast cancer in April 2001. Surgery followed, including the removal of 37 lymph nodes. Testing with PathVysion, a gene-based test from Abbott Molecular, confirmed that Donna was among the estimated one-in-four breast cancer patients whose HER-2 gene was malfunctioning, creating additional copies of itself.» More

Abbott Park, Illinois, and San Ramon, California, October 19, 2004 - Abbott and BioGenex Laboratories today announced an agreement to distribute and market a new system that will fully automate molecular diagnostic tests that employ Abbott's proprietary Fluorescence in situ Hybridization (FISH) technology.» More